Nomogram models predicting prognosis for patients with t(8;21) acute myeloid leukemia: a SEER-based study

References

• Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–565. doi: 10.1200/JCO.2010.30.7405
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi: 10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48(12):1551–1556. doi: 10.1038/ng.3709
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365. doi: 10.1182/blood-2009-11-254441
   PubMed Web of Science ®Google Scholar
• Yushu H, Shougeng B, Zhijian X, et al. Acute myeloid leukemia M2b. Haematologica. 1999;84(3):193–194.
   PubMed Web of Science ®Google Scholar
• Solh M, Yohe S, Weisdorf D, et al. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. Am J Hematol. 2014;89(12):1121–1131. doi: 10.1002/ajh.23821
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336. doi: 10.1182/blood-2002-03-0772
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741–3750. doi: 10.1200/JCO.2004.03.012
   PubMed Web of Science ®Google Scholar
• Acharya UH, Halpern AB, Wu QV, et al. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). J Drug Assess. 2018;7(1):51–53. doi: 10.1080/21556660.2018.1492925
   PubMed Web of Science ®Google Scholar
• Borate UM, Mineishi S, Costa LJ. Nonbiological factors affecting survival in younger patients with acute myeloid leukemia. Cancer. 2015;121(21):3877–3884. doi: 10.1002/cncr.29436
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi: 10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Bianco FJ Jr. Nomograms and medicine. Eur Urol. 2006;50(5):884–886. doi: 10.1016/j.eururo.2006.07.043
   PubMed Web of Science ®Google Scholar
• Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417–435. doi: 10.1007/s10552-008-9256-0
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Chen C, Wang P, Wang C. Prognostic nomogram for adult patients with acute myeloid leukemia: a SEER database analysis. Medicine (Baltimore). 2019;98(21):e15804. doi: 10.1097/MD.0000000000015804
   PubMed Web of Science ®Google Scholar
• Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049–2061.
   PubMed Web of Science ®Google Scholar
• Zuo Z, Zhang G, Song P, et al. Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–3950. doi: 10.1245/s10434-020-09362-0
   PubMed Web of Science ®Google Scholar
• Zhang SL, Chen C, Rao QW, et al. Incidence, prognostic factors and survival outcome in patients with primary hepatic lymphoma. Front Oncol. 2020;10:750. doi: 10.3389/fonc.2020.00750
   PubMedGoogle Scholar
• Xing Z, Zhu X, Li Z, et al. Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: a SEER-based study. Front Oncol. 2022;12:989366. doi: 10.3389/fonc.2022.989366
   PubMed Web of Science ®Google Scholar
• Lin D, Zhou C, Wei H, et al. Characteristics and treatment outcomes in 822 adult patients with acute myeloid leukemia: a single center experience. Zhonghua Xue Ye Xue Za Zhi. 2014;35(12):1058–1064.
   PubMedGoogle Scholar
• Prébet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–4753. doi: 10.1200/JCO.2008.21.0674
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27. doi: 10.6004/jnccn.2021.0002
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705–5717. doi: 10.1200/JCO.2005.15.610
   PubMed Web of Science ®Google Scholar
• Winer ES. Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment. Hematol Oncol Clin North Am. 2020;34(2):449–463. doi: 10.1016/j.hoc.2019.11.003
   PubMed Web of Science ®Google Scholar
• Szotkowski T, Muzik J, Voglova J, et al. Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic. Neoplasma. 2010;57(6):578–589. doi: 10.4149/neo_2010_06_578
   PubMed Web of Science ®Google Scholar
• Matthews A, Pratz KW. Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program. 2022;2022(1):23–29. doi: 10.1182/hematology.2022000324
   PubMedGoogle Scholar